|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0230 - 0.0230|
|52 Week Range||0.0004 - 0.1200|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Roadman and PanAsia will collaborate to integrate the Company’s recently acquired portfolio company CLOV Biopharma Corp’s (CBP) utilization of cedar leaf oil vapour in a variety of both clinical laboratory and real world commercial scenarios into the Asia Pacific region.
CLOV Biopharma Corp. is focused on conducting further research and development of cedar leaf oil vapour (“CLOV”) for the purposes of preventing the spread of Coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial viruses. CBP is working in partnership with Dr. James Hudson, Ph.D, who is widely considered to be one of the foremost virologists in Canada, in an effort to expand upon and potentially commercialize his many years of study and scientific analysis involving the antimicrobial and antiviral properties of cedar leaf (Thuja plicata) oil.